|
Business Wire Health: Pharmaceutical News
|
Health: Pharmaceutical News Distributed by Business Wire
|
|
-
EpiCept Files for AmiKet™ Fast Track Designation
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced that it has filed for Fast Track designation for AmiKet™ (amitriptyline 4%, ketamine 2% cream) for the treatment for chemotherapy-induced peripheral neuropathy (CIPN) with the U.S. Food and Drug Administration (FDA). AmiKet™ is a prescription topical cream under late stage clinical development by EpiCept for the treatment of peripheral neuropathic pain. Jack Tall
-
Exelixis Announces February 8th Webcast of Fourth Quarter & Full Year 2011 Financial Results Conference Call
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company’s financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast ma
-
Clovis Oncology to Present at the Leerink Swann Global Healthcare Conference and Citi 2012 Global Health Care Conference in February
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Company management will present at the Leerink Swann Global Healthcare Conference on Wednesday, February 15, 2012 at 1:30 PM Eastern Time and the Citi 2012 Global Health Care Conference on Wednesday, February 29, 2012 at 8:30 AM Eastern Time. Both conferences will be held at the Waldorf-Astoria Hotel in New York City. A live webcast of each presentation will be accessible through the investor relations sec
-
Clinical Research Advantage, Inc. Named among az magazine’s Top 25 Workplaces for Women
TEMPE, Ariz.--(BUSINESS WIRE)--CLINICAL RESEARCH ADVANTAGE, INC. NAMED AMONG AZ MAGAZINE’S TOP 25 WORKPLACES FOR WOMEN
-
Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX CAPSULES®
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company has partnered with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI) to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES® (tizanidine hydrochloride). Tizanidine hydrochloride capsules is a short-acting drug indicated for the management of spasticity. Because of the short duration of effect, treatment with tizanidine
-
Synta Pharmaceuticals Sells Additional 1,050,000 Shares of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta (NASDAQ: SNTA) today announced the completion of the sale of 1,050,000 additional shares of its common stock aggregate net proceeds from the offering were approximately $32.9 million.
-
NPS Pharmaceuticals to Present at Upcoming Conferences
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the 14th Annual Bio CEO and Investor Conference in New York on Monday, February 13, 2012 at 9:30 a.m. ET and the Leerink Swann Global Healthcare Conference on Thursday, February 16, 2012 at 9:00 a.m. ET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the inve
-
Zalicus to Present at BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus to present at Annual BIO CEO & Investor Conference
-
Synchroneuron Completes $6 Million Series A Financing to Fund Development of a Novel Treatment for Movement Disorders
WALTHAM, Mass.--(BUSINESS WIRE)--Synchroneuron Completes $6 Million Series A Financing to Fund Development of a Novel Treatment for Movement Disorders
-
Alkermes’ Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 2:30 p.m. EST (7:30 p.m. GMT) from the Waldorf=Astoria Hotel in New York City. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days. Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expert
|
